Stephen Liu, MD

Articles

Audience Q&A: Emerging Therapeutic Targets in Advanced NSCLC

August 12th 2022

Closing out their discussion on the treatment paradigm of advanced NSCLC, key opinion leaders review emerging targets and ongoing clinical trials.

CheckMate 9LA: Dual IO Therapy With Chemotherapy in Advanced NSCLC

August 5th 2022

Shared insight on the CheckMate 9LA trial, which combined dual IO therapy with chemotherapy in the setting of advanced non–small cell lung cancer.

Dual IO Therapy in Advanced NSCLC: Long-Term Followup From CheckMate 227

August 5th 2022

Expert perspectives on the CheckMate 227 clinical trial, which combined ipilimumab and nivolumab IO therapy in patients with advanced NSCLC.

Discontinuing Chemoimmunotherapy in Advanced NSCLC

July 29th 2022

A brief discussion on when it is appropriate to discontinue chemoimmunotherapy in patients with advanced non–small cell lung cancer.

Chemoimmunotherapy Combinations in Advanced NSCLC

July 29th 2022

Shifting their focus to chemoimmunotherapy combinations in advanced NSCLC, experts review clinical trial data from KEYNOTE-189, IMpower150, and EMPOWER-Lung 3.

Advanced NSCLC: IO Monotherapy Selection Based on PD-L1 Expression

July 22nd 2022

Shared insight on the optimal selection and use of single-agent immunotherapy guided by the testing and expression of PD-L1.

Toxicity Profiles of Immunotherapy Agents in Advanced NSCLC

July 22nd 2022

A brief review of AEs seen with immunotherapy in advanced non–small cell lung cancer followed by advice on how to nuance safety data in this setting.

Clinical Management of NTRK+ Advanced NSCLC

November 8th 2021

Ben Levy, Mark Socinski, and Stephen Liu describe the current treatment options for patients with NTRK+ NSCLC. They also summarize recent clinical data for agents that target NTRK.

Clinical Management of RET+ Advanced NSCLC

November 1st 2021

Mark Socinski and Stephen Liu describe the current treatment options for patients with RET+ NSCLC. They also summarize recent clinical data for agents that target RET.

RET Alterations in Advanced NSCLC

November 1st 2021

Ben Levy, Mark Socinski, and Stephen Liu explain the role of a RET alteration in NSCLC and its value as a targetable biomarker.

Clinical Management of ROS1+ Advanced NSCLC

October 25th 2021

Ben Levy, Mark Socinski, and Stephen Liu describe the current treatment options for patients with ROS1+ NSCLC. They also summarize recent clinical data for agents that target ROS1.

ROS1 Alterations in Advanced NSCLC

October 25th 2021

Ben Levy, Mark Socinski, and Stephen Liu explain the role of a ROS1 alteration in NSCLC and its value as a targetable biomarker.

Clinical Management of ALK+ Advanced NSCLC

October 18th 2021

Ben Levy, Mark Socinski, and Stephen Liu describe the current treatment options for patients with ALK+ NSCLC. They also summarize recent clinical data for ALK inhibitors.

ALK Alterations in Advanced NSCLC

October 18th 2021

Ben Levy, Mark Socinski, and Stephen Liu explain the role of an ALK alteration in NSCLC and its value as a targetable biomarker.

Testing for Gene Alterations and Protein Expression in Advanced NSCLC

October 11th 2021

Ben Levy, Mark Socinski, and Stephen Liu explain the various types of genetic alterations and protein expressions that are targetable in NSCLC and the crucial role of comprehensive genetic testing at the time of diagnosis and at the time of disease progression.

Overview of Targeted Therapies, Improved Outcomes, and Unmet Needs in Advanced NSCLC

October 11th 2021

An increased understanding of driver gene alterations in advanced non–small cell lung cancer (NSCLC) has led to the development of targeted therapies that offer improved patient outcomes. Ben Levy, MD; Mark A. Socinski, MD; and Stephen Liu, MD, share their thoughts on the emerging treatment landscape and remaining unmet needs.

Dr. Liu on the Rationale for the ARROW Trial in RET Fusion+ NSCLC

June 22nd 2021

Stephen Liu, MD, discusses the rationale for the ongoing phase 1/2 ARROW trial in RET fusion–positive non–small cell lung cancer.

Dr. Liu on Common NRG1 Fusion Partners in NSCLC

April 29th 2021

Stephen Liu, MD, discusses common NRG1 fusion partners in patients with non–small cell lung cancer.

Dr. Liu on the Rationale for Examining Afatinib in NSCLC Harboring NRG1 Fusions

February 17th 2021

Stephen Liu, MD, discusses the rationale for examining afatinib in patients with non–small cell lung cancer harboring NRG1 fusions.

Dr. Liu on Emerging Data With Novel ADCs in NSCLC

January 30th 2021

Stephen Liu, MD, discusses emerging research on antibody–drug conjugate in non–small cell lung cancer that were presented during the 2020 World Conference on Lung Cancer.